Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Division of Hematology and Oncology, Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center, New York, NY, USA.
Cancer Cell. 2020 Nov 9;38(5):629-646. doi: 10.1016/j.ccell.2020.09.018. Epub 2020 Oct 1.
Patients with cancer have been disproportionately affected by the COVID-19 pandemic. This effect has included the adverse outcomes in patients with cancer who develop COVID-19, the impact of the COVID-19 pandemic on the delivery of cancer care, and the severe disruption to cancer research. However, patients with cancer are a heterogeneous population, and recent studies have now documented factors that allow risk stratification of patients with cancer in order to optimize care. In this review, we highlight data at the intersection of COVID-19 and cancer, including the biological interplay between the two diseases and practical recommendations for the treatment of patients with cancer during the pandemic. We additionally discuss the potential long-lasting impact of the pandemic on cancer care due to its deleterious effect on cancer research, as well as biological insights from the cancer research community that could help develop novel therapies for all patients with COVID-19.
癌症患者受 COVID-19 大流行的影响不成比例。这种影响包括罹患 COVID-19 的癌症患者的不良结局、COVID-19 大流行对癌症治疗的影响，以及对癌症研究的严重干扰。然而，癌症患者是一个异质人群，最近的研究已经记录了允许对癌症患者进行风险分层的因素，以便优化护理。在这篇综述中，我们强调了 COVID-19 和癌症之间的交叉数据，包括这两种疾病之间的生物学相互作用，以及在大流行期间治疗癌症患者的实用建议。我们还讨论了大流行对癌症治疗的潜在持久影响，因为它对癌症研究产生了有害影响，以及癌症研究界的生物学见解，这些见解可能有助于为所有 COVID-19 患者开发新的治疗方法。
Zotero 插件